Prime Medic Group Fined for Unlawful Weight Loss Medicine Advertising

TGA Australia Media Releases

Filed February 2nd, 2026

Detected March 12th, 2026

Summary

The Therapeutic Goods Administration (TGA) has issued infringement notices totaling $23,760 to Prime Medic Group and an individual for allegedly unlawfully advertising prescription-only weight loss medicines. Prime Medic Group paid the fines in January 2026.

View original document View source feed page

What changed

The Therapeutic Goods Administration (TGA) has issued infringement notices to Prime Medic Group Pty Ltd and an individual for alleged unlawful advertising of prescription-only weight loss medicines, Ozempic and Mounjaro. Prime Medic Group was fined $19,800 and an individual $3,960, both of which were paid in January 2026. The TGA alleges that Prime Medic advertised these prescription-only medicines directly to consumers between January and July 2025, which is prohibited under the Therapeutic Goods Act 1989 as it can undermine the patient-practitioner relationship and create inappropriate demand. Additionally, the advertising allegedly promoted the use of therapeutic goods for serious diseases without TGA approval.

This enforcement action highlights the TGA's commitment to policing advertising of therapeutic goods. Healthcare providers and pharmaceutical companies must ensure their advertising practices comply with the Therapeutic Goods Act 1989, particularly regarding direct-to-consumer advertising of prescription medicines and restricted or prohibited representations. Failure to comply can result in significant penalties, including infringement notices, directions, and potential legal proceedings. Regulated entities should review their advertising strategies to ensure adherence to these regulations.

What to do next

Review advertising practices for prescription-only medicines to ensure compliance with the Therapeutic Goods Act 1989.
Ensure no direct-to-consumer advertising of prescription-only therapeutic goods occurs.
Verify that all advertising claims comply with restrictions on representations for serious diseases or conditions.

Penalties

Prime Medic Group fined $19,800; an individual fined $3,960. Both paid in January 2026.

Source document (simplified)

Prime Medic Group issued infringement notices for alleged unlawful advertising of weight loss medicines

Published

2 February 2026

Listen
Print
Share
- LinkedIn
- (Twitter)
- Facebook
- Email The Therapeutic Goods Administration (TGA) has issued infringement notices to Prime Medic Group Pty Ltd (Prime Medic) and an individual for the alleged unlawful advertising of weight loss medicines in contravention of the Therapeutic Goods Act 1989 (the Act).

One infringement notice for $19,800 was issued to Prime Medic, and one for $3,960 was issued to the individual. Prime Medic and the individual paid the infringement notices in January 2026.

Prime Medic operates an online telehealth platform offering consultations with doctors. It is alleged that Prime Medic advertised prescription-only weight loss medicines, Ozempic and Mounjaro, directly to consumers between at least January and July 2025.

Advertising prescription-only medicines directly to consumers is prohibited under the Act, as it can create inappropriate demand and undermine the relationship between patients and their treating health practitioner. Decisions about appropriate treatment options should be made by a patient, in consultation with their health professional.

It is also alleged that the advertising promoted the use of therapeutic goods for the treatment of serious diseases, conditions or disorders. Such references are known as restricted or prohibited representations and are not allowed to be included in advertising for therapeutic goods unless approval or permission is given by the TGA.

Health providers must understand their legal obligations before advertising therapeutic goods.

The TGA will continue to take action where serious non-compliance with the Act is identified in accordance with our regulatory compliance framework. This may include issuing infringement notices, directions and prevention notices, or civil or criminal proceedings.

If you suspect non-compliance in relation to therapeutic goods, or their advertising, you can report it to the TGA at any time.

Contact for members of the media: